These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37940743)

  • 1. The value of GLI1 and p16 immunohistochemistry in the premolecular screening for GLI1-altered mesenchymal neoplasms.
    Machado I; Agaimy A; Giner F; Navarro S; Michal M; Bridge J; Claramunt R; López-Guerrero JA; Alcacer J; Linos K; Llombart-Bosch A
    Virchows Arch; 2024 May; 484(5):765-775. PubMed ID: 37940743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLI1 Immunohistochemistry Distinguishes Mesenchymal Neoplasms With GLI1 Alterations From Morphologic Mimics.
    Parrack PH; Mariño-Enríquez A; Fletcher CDM; Hornick JL; Papke DJ
    Am J Surg Pathol; 2023 Apr; 47(4):453-460. PubMed ID: 36693363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
    Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
    Mod Pathol; 2024 Jun; 37(6):100494. PubMed ID: 38621503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma.
    Kobayashi A; Sakuma T; Fujimoto M; Jimbo N; Hirose T
    Appl Immunohistochem Mol Morphol; 2019; 27(10):758-763. PubMed ID: 31145104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLI1-Altered Soft Tissue Tumors of the Head and Neck: Frequent Oropharyngeal Involvement, p16 Immunoreactivity, and Detectable Alterations by DDIT3 Break Apart FISH.
    Palsgrove DN; Rooper LM; Stevens TM; Shin C; Damm DD; Gagan J; Bridge JA; Thompson LDR; Koduru PR; Bishop JA
    Head Neck Pathol; 2022 Dec; 16(4):1146-1156. PubMed ID: 35933574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superficial GLI1-amplified mesenchymal neoplasms: Expanding the spectrum of an emerging entity which reaches the realm of dermatopathology.
    Machado I; Hosler GA; Traves V; Claramunt R; Sanmartín O; Santonja C; Carvajal N; Zazo S; Requena L; Alfonso VS; Domenech EV; Llombart-Bosch A; Bridge JA; Linos K
    J Cutan Pathol; 2023 Jun; 50(6):487-499. PubMed ID: 36316249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLI1-altered mesenchymal tumor: a clinicopathological and molecular analysis of ten additional cases of an emerging entity.
    Liu J; Mao R; Lao IW; Yu L; Bai Q; Zhou X; Wang J
    Virchows Arch; 2022 May; 480(5):1087-1099. PubMed ID: 34779913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive Nested Glomoid Neoplasm: Clinicopathologic Analysis of 20 Cases of a Mesenchymal Neoplasm With Frequent GLI1 Alterations and Indolent Behavior.
    Papke DJ; Dickson BC; Oliveira AM; Sholl LM; Fletcher CDM
    Am J Surg Pathol; 2023 Jan; 47(1):12-24. PubMed ID: 36395474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
    Thway K; Flora R; Shah C; Olmos D; Fisher C
    Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Accuracy of Immunohistochemical Expression of p16, MDM2, and CDK4 in Well-Differentiated and De-Differentiated Liposarcoma in MDM2 Fluorescent in situ Hybridisation Confirmed Cases.
    Aslam A; Din HU; Qadir A; Aslam U; Humayoun S; Ahmed W
    J Coll Physicians Surg Pak; 2024 Sep; 34(9):1051-1055. PubMed ID: 39262004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis.
    Kerr DA; Cloutier JM; Margolis M; Mata DA; Rodrigues Simoes NJ; Faquin WC; Dias-Santagata D; Chopra S; Charville GW; Wangsiricharoen S; Lazar AJ; Wang WL; Rosenberg AE; Tse JY
    Mod Pathol; 2024 Feb; 37(2):100386. PubMed ID: 37992966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors.
    Saoud C; Agaimy A; Dermawan JK; Chen JF; Rosenblum MK; Dickson BC; Dashti N; Michal M; Kosemehmetoglu K; Din NU; Albritton K; Agaram NP; Antonescu CR
    Am J Surg Pathol; 2024 Oct; 48(10):1302-1317. PubMed ID: 38934567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
    He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
    Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions.
    Antonescu CR; Agaram NP; Sung YS; Zhang L; Swanson D; Dickson BC
    Am J Surg Pathol; 2018 Apr; 42(4):553-560. PubMed ID: 29309307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
    Hemminger JA; Iwenofu OH
    Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics.
    Kang Y; Horvai AE
    Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):58-63. PubMed ID: 26509911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.